Drugs / Egg-derived influenza virus vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00630331 | Oct 2007 → Jul 2008 | influenza | Novartis Vaccines | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Egg-derived influenza virus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00630331 ↗ |
| Known as | Agrippal | “METHODS: A total of 11,404 study participants aged 18-49 years were randomized equally to receive CCIV (Optaflu; n = 3828), TIV (Agrippal; n = 3676), or placebo (n = 3900).” PMID 20868284 ↗ Nov 2010 |
| Modality | Vaccine | “Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.” PMID 20868284 ↗ Nov 2010 |
| Route | Intramuscular | “administered in the deltoid muscle.” NCT00630331 ↗ |